AllStripes
AllStripes is a San Francisco healthcare technology company that operates a B2B2C platform enabling rare disease patients to contribute de-identified health records, then licenses the aggregated dataset to biopharmaceutical companies for research and clinical trial support.
- Company typePrivate
- Founded2017
- HeadquartersSan Francisco, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What AllStripes does
AllStripes is a San Francisco-based healthcare technology company founded in 2017 that operates a B2B2C platform enabling rare disease patients to contribute their de-identified longitudinal health records to support biopharma research and clinical trials. The platform's core function is collecting, de-identifying, and organizing medical records contributed by patients, then making aggregated, de-identified datasets available to biopharmaceutical companies conducting rare disease research. Patients serve as the data-contributing side, while biopharmaceutical companies serve as the data-buying side for research, clinical trial design, and recruitment support. The company specializes narrowly in rare diseases, where small global patient populations make data assembly otherwise difficult.
The business model is data monetization: AllStripes licenses access to its proprietary rare-disease dataset to biopharma customers rather than charging patients. Pricing is not publicly disclosed and no customer logos have been revealed. AllStripes has raised approximately $67 million across four funding rounds through August 2021, with the $50 million Series B led by Lux Capital and including strategic healthcare investors McKesson Ventures and Medidata alongside Spark Capital, Maveron, Jazz Venture Partners, Bossa Invest, Trajectory Ventures, Garuda Ventures, Village Global, and Shasta Ventures. The headcount is reported in the 51–100 range.
Following the Series B, AllStripes has publicly committed to expanding its rare disease research programs and operations across additional countries. The company is led by co-founder and CEO Nancy Yu, with Leo Vand serving as VP of Engineering and Joe Walsh as a Vice President. No AI/ML capabilities, patents, regulatory actions, mergers, acquisitions, or leadership changes beyond the named team are disclosed in the available source material.
AllStripes firmographics
Firmographics- Name
- AllStripes
- Website
- https://allstripes.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- AllStripes is a San Francisco healthcare technology company that operates a B2B2C platform enabling rare disease patients to contribute de-identified health records, then licenses the aggregated dataset to biopharmaceutical companies for research and clinical trial support.
- Ownership category
- akta.pro rank
Where AllStripes is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AllStripes business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Data Access/Licensing to Biopharma: AllStripes generates revenue by enabling access to de-identified patient health records for biopharma companies conducting rare disease research and clinical trials. Patients contribute their health records which are then made available (in de-identified form) to pharmaceutical researchers.
AllStripes product offering
Product offeringCore offering
AllStripes operates a healthcare technology platform that enables rare disease patients to share their de-identified health records and then licenses access to this aggregated, longitudinal dataset to biopharmaceutical companies to support rare disease research, clinical trial design, and patient recruitment.
Product overview
AllStripes offers a healthcare technology platform that enables patients to share their de-identified health records to support biopharma research and clinical trials focused on rare diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- AllStripes Platform A healthcare technology platform that enables rare disease patients to contribute their de-identified health records and provides biopharmaceutical companies with access to longitudinal patient data for rare disease research and clinical trials.
Companies that use AllStripes
Customer profileSegments2 records
Ideal customer profiles2 records
AllStripes technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
AllStripes partnerships and signals
Strategic signalScale indicators2 records
Recent moves4 records
Expansion highlights4 records
AllStripes competitors and assessment
Company assessmentOthers
- Health Catalyst: Healthcare data and analytics platform primarily serving health systems and providers. Indirectly comparable as a healthcare data platform; less direct overlap since its buyer base skews provider rather than biopharma.
Direct peers
- PicnicHealth: Patient-mediated platform that aggregates medical records from multiple points of care and partners with biopharma and academic centers on research studies, including rare disease. Closest direct competitor with the same B2B2C patient-to-biopharma data model.
- PatientsLikeMe: Patient-reported outcomes and real-world data platform (now under Optum) that aggregates patient experiences to support research. Highly comparable patient-to-researcher data-sharing model, though historically weighted toward self-reported rather than EHR data.
Broad incumbents
- Flatiron Health: Roche-owned real-world evidence and EHR data platform serving oncology biopharma. Competes for biopharma RWD budgets and clinical trial data needs, though its primary focus is oncology rather than rare disease.
- IQVIA: Global clinical research services and real-world data giant offering biopharma data, analytics, and trial solutions. Overlaps with AllStripes on real-world data licensing and clinical trial enablement, but at much greater scale and breadth.
- Medidata Solutions: Dassault Systèmes subsidiary providing clinical trial technology, data, and analytics to biopharma. Also a strategic investor in AllStripes. Competes in the broader clinical-trial data and digital trial enablement space.
- Verily (Alphabet): Alphabet-owned health technology and data company running clinical research, real-world evidence, and precision medicine programs. Competes in the broader patient-data-for-research category with far greater capital and infrastructure.
Emerging players
- RARE-X: Non-profit/cross-stakeholder data platform purpose-built for collecting and sharing rare disease patient data with researchers. Operates in AllStripes' rare-disease niche but with a non-profit/registry-leaning model.
- Seqster: Longitudinal patient data platform that consolidates EHR, genomics, and wearable data for research and clinical trials. Comparable in aggregating multi-source patient records for biopharma, though broader than rare disease.
- TriNetX: Global health research network aggregating EHR data from participating hospitals for clinical trial design, patient recruitment, and real-world evidence. Comparable EHR-to-biopharma data flow, though provider-mediated rather than patient-mediated.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
AllStripes social profiles
Digital presenceAllStripes financial estimates
Financial estimateRevenue estimate
Valuation estimate
AllStripes leadership team
Management profileNumber of profiles
Profiles3 records
AllStripes funding detail
Funding detailFunding overview
Funding rounds4 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AllStripes M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AllStripes
What does AllStripes do?
AllStripes operates a healthcare technology platform that enables rare disease patients to share their de-identified health records and then licenses access to this aggregated, longitudinal dataset to biopharmaceutical companies to support rare disease research, clinical trial design, and patient recruitment.
Is AllStripes a public or private company?
AllStripes is a private company. It is classified as venture growth investor backed and is currently operating.
When was AllStripes founded?
AllStripes was founded in 2017. It employs 51 to 100 people.
Where is AllStripes based?
AllStripes is headquartered in San Francisco, United States, in the North America region.
How does AllStripes make money?
One revenue line is on record: data Access/Licensing to Biopharma.
Who are AllStripes's main competitors?
Health Catalyst is listed as an others. Direct peers are PicnicHealth and PatientsLikeMe. Broad incumbents are Flatiron Health, IQVIA, Medidata Solutions and Verily (Alphabet). Emerging players are RARE-X, Seqster and TriNetX.
Does AllStripes have an API?
No public API is recorded for AllStripes.